Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial
(1)
,
(2)
,
(3)
,
(4)
,
(4, 5)
,
,
(6)
,
(7)
,
(8, 9)
,
(10, 11)
,
(12)
,
(13)
,
(14)
,
(4)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
2
3
4
5
6
7
8
9
10
11
12
13
14
Sibylle Masse
- Fonction : Auteur
Alexis Caulier
- Fonction : Auteur
- PersonId : 1151781
- IdRef : 194466000
Olivier Hermine
- Fonction : Auteur
- PersonId : 756140
- ORCID : 0000-0003-2574-3874
- IdRef : 069884927
Steven Le Gouill
- Fonction : Auteur
- PersonId : 761203
- ORCID : 0000-0001-9840-2128
Résumé
Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial